Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: Results of a Phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial☆
Introduction
The incidence of renal cell carcinoma has increased steadily to rank tenth amongst the most common cancers [1]. Approximately two-thirds of patients present with organ confined disease amenable to a potentially curative nephrectomy [2], [3]. Recurrence rates post nephrectomy are high particularly in patients with larger more aggressive tumours. This has led to the development of several risk stratification algorithms based on histological features of the resected specimen to identify patients most at risk of recurrence [4].
The need for an effective adjuvant treatment post nephrectomy in patients deemed to be at most risk of developing metastatic disease post nephrectomy has long been recognised.
The presentation of results of a triple regime combining chemo-immunotherapy in 1993 by Atzpodien [5] with response rates of 40% which represented a significant improvement compared with standard therapy at that time (interferon alone) [6] led to the development of a European Organisation for Research and Treatment of Cancer (EORTC) led trial in the adjuvant setting.
This trial was set up to compare, in patients at high risk of recurrence after nephrectomy for renal cell carcinoma, adjuvant treatment with triple combination therapy (5-flurouracil, alpha-interferon and interleukin-2) versus observation alone in terms of disease free survival, overall survival and quality of life. High risk patients were defined as those with high pT stage (T3b, T3c or T4), or the presence of positive nodes (N1 or N2) or microscopic positive surgical margins, or the presence of microvascular invasion [7].
The objectives of the trial were to determine if triple combination therapy improves either disease free survival or overall survival in high risk renal cell carcinoma patients who are macroscopically tumour free after radical surgery and to evaluate the quality of life in the treatment and observation groups.
Section snippets
Methods
This was an international multicentre, two arm, parallel, randomised phase III trial.
Eligible patients had undergone surgical resection of their primary renal cell carcinoma tumour within 12 weeks prior to randomisation, had clinical N+ disease removed and had no metastatic disease or macroscopic residual disease as confirmed within 2–4 weeks prior to randomisation by CT or MRI of abdomen plus chest X-ray. Patients had a histologically proven stage T3b, T3c, T4 tumour or any pT stage and nodal
Results
Between May 1998 and March 2007, 309 patients were randomised (154 treatment, 155 observation). Patients were followed up until database lock in January 2011. The final patient was randomised on 21st March 2007.
The median follow-up time was virtually identical in both arms and overall was 7 years (95% confidence interval (CI) (6.4, 7.6)). Twenty-two (7.1%) patients were lost to follow-up. Seventy-nine percent of living patients had follow-up within 12 months of the cut-off date for data return.
Discussion
The results of this trial show no significant benefit for patients at high risk of recurrence post nephrectomy for organ confined or locally advanced renal cell carcinoma in terms of disease free survival or overall survival. The treatment regime generated considerable toxicity but quality of life in the treatment group was comparable to the observation group by 6 months.
The high response rates reported in the initial series by Atzpodien [11] for the triple regime has not been replicated in
Funding
This trial was supported in part by Cancer Research UK (previously Cancer Research Campaign). The EORTC is grateful to Roche and Chiron for supporting this study through Educational Grants and for a grant from the EORTC Charitable Trust.
Conflict of interest statement
None declared.
Acknowledgement
The EORTC would also like to acknowledge the very substantial contribution to this study from Dr. Pieter De Mulder (Nijmegen) who unfortunately passed away before the trial was completed.
References (14)
- et al.
Renal cell carcinoma: survival and prognostic factors
Urology
(1986) - et al.
Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy
J Urol
(2005) - et al.
Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system
J Urol
(2005) - et al.
Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer
Eur J Cancer
(1993) - et al.
Microscopic vascular invasion is the most relevant prognosticator after radical nephrectomy for clinically nonmetastatic renal cell carcinoma
J Urol
(1997) - et al.
A randomised trial of interferon alpha versus interferon alpha, IL-2 and 5 FU in patients with previously untreated metastatic renal cancer: the results of an intergroup study of the MRC (REO4) and the EORTC GU Group (30012)
Lancet
(2010) - et al.
An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial
Lancet
(2008)
Cited by (36)
Adjuvant therapy for renal cell carcinoma: A systematic review of current landscape and future directions
2023, Critical Reviews in Oncology/HematologyThe Promise of Neoadjuvant and Adjuvant Therapies for Renal Cancer
2023, Urologic Clinics of North AmericaAdjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives
2021, Cancer Treatment ReviewsAdjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature
2018, Clinical Genitourinary CancerCitation Excerpt :No differences were observed in 3-year DFS (61.3%; 95% CI, 53.5-69 vs. 50.4%; 95% CI, 42.5-58.4) or 5-year OS (69.7%; 95% CI, 62.2-77.3 vs. 62.8%; 95% CI, 54.8-70.8) rates. Furthermore, significant toxicity rates were observed, which resulted in discontinuation of therapy in 35% of the treated patients.15 Taken together, alone or in combination, IL-2 and IFN-α cytokines have not shown OS or DFS benefits in nmRCC patients treated with nephrectomy.
Adjuvant therapy for locally advanced renal cell carcinoma: A meta-analysis and systematic review
2018, Urologic Oncology: Seminars and Original InvestigationsCitation Excerpt :It did not produce any other studies for evaluation through checking reference lists. Considering these trials, 8 trials of the 12 eligible trials had mature OS data [11,12,18,25–28,30], all trials reported directly DFS data [11,12,17–19,24–30], one trial did not directly provide HRs, and 6 trials had related data to safety [17–19,24,27,30]. Table 1 presents the process of study identification and selection.
Postoperative surveillance imaging for patients undergoing nephrectomy for renal cell carcinoma
2015, Urologic Oncology: Seminars and Original Investigations
- ☆
Clinical Trial Number: ISRCTN16387614 (http://www.isrctn.org), NCT00053807 (clinicaltrials.gov).